Estrogen receptors restrict tumor-promoting inflammation in K-ras mutant lung cancer

雌激素受体限制 K-ras 突变肺癌中促肿瘤的炎症

基本信息

项目摘要

Abstract More patients die from lung cancer than from any other cancer type each year in the United States. Moreover, lung cancers with K-ras driver mutations are resistant to targeted therapies. Therefore, there is an unmet need to find druggable targets downstream of K-ras. Tumor-promoting inflammation occurs frequently as a result of K-ras mutations that activate the NF-κB pathway, the production of interleukin 6, and activation of its downstream transcription factor STAT3. However, when we knock out STAT3 in tumor cells in mice, females have fewer tumors, but males have more. This sex disparity is driven by overactivation of NF-κB in males, but in females, estrogen signaling reduces NF-κB and tumor-promoting inflammation. This protective phenotype requires estrogen receptors (ERs), nuclear hormone receptors that bind estrogen and interact with NF-κB. There are two genes for ERs: ERα and ERβ. ERβ is the major ER isoform expressed in lung tissue, and ERα is mainly in immune cells. Accordingly, I hypothesize that in the absence of STAT3 in the lung epithelium, ERα and ERβ signaling is protective in K-ras mutant lung cancer by inhibiting NF-κB-driven pro-tumor inflammation. I have two specific aims to test this hypothesis, one aim for each of the cellular compartments of interest: tumor cells and myeloid cells. Aim 1: I will knock out ERβ in tumors to determine if it is required for cancer protection in females. Aim 2: since ERα predominates in tumor-infiltrating myeloid immune cells, I will knock out ERα in myeloid cells to determine if it is also required for cancer protection. Successful completion of these aims will further explain the mechanism of ER-dependent lung cancer protection, with potential for estrogen and ERα/ERβ to play a novel therapeutic role. Since clinical trials for STAT3 inhibitors have begun, it is important to understand the sex- specific outcomes of targeting STAT3. Our results will guide clinicians to better personalize therapy by taking sex hormones into account when treating patients. They will also shed light on the mechanism of resistance to currently available immunotherapies and provide alternative modalities.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Joseph Clowers其他文献

Michael Joseph Clowers的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Joseph Clowers', 18)}}的其他基金

Estrogen receptors restrict tumor-promoting inflammation in K-ras mutant lung cancer
雌激素受体限制 K-ras 突变肺癌中促肿瘤的炎症
  • 批准号:
    10583464
  • 财政年份:
    2022
  • 资助金额:
    $ 3.42万
  • 项目类别:

相似海外基金

Uncovering colorectal cancer etiology and biology by integrating proteomics with other omics data
通过将蛋白质组学与其他组学数据相结合,揭示结直肠癌的病因学和生物学
  • 批准号:
    10585424
  • 财政年份:
    2023
  • 资助金额:
    $ 3.42万
  • 项目类别:
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and Europeans
发现因果蛋白标记物以提高非洲人和欧洲人对前列腺癌病因的了解和风险预测
  • 批准号:
    10446594
  • 财政年份:
    2022
  • 资助金额:
    $ 3.42万
  • 项目类别:
Uncovering causal protein markers to improve prostate cancer etiology understanding and risk prediction in Africans and Europeans
发现因果蛋白标记物以提高非洲人和欧洲人对前列腺癌病因的了解和风险预测
  • 批准号:
    10647719
  • 财政年份:
    2022
  • 资助金额:
    $ 3.42万
  • 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    10307055
  • 财政年份:
    2020
  • 资助金额:
    $ 3.42万
  • 项目类别:
Uncovering Roles of Metabolites in Colorectal Cancer Etiology
揭示代谢物在结直肠癌病因学中的作用
  • 批准号:
    10224955
  • 财政年份:
    2020
  • 资助金额:
    $ 3.42万
  • 项目类别:
Uncovering Roles of Metabolites in Colorectal Cancer Etiology
揭示代谢物在结直肠癌病因学中的作用
  • 批准号:
    10201868
  • 财政年份:
    2020
  • 资助金额:
    $ 3.42万
  • 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    10527364
  • 财政年份:
    2020
  • 资助金额:
    $ 3.42万
  • 项目类别:
Life course body fatness and physical activity, and ovarian cancer etiology
生命历程身体脂肪和体力活动以及卵巢癌病因
  • 批准号:
    435914
  • 财政年份:
    2020
  • 资助金额:
    $ 3.42万
  • 项目类别:
    Operating Grants
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    10093129
  • 财政年份:
    2020
  • 资助金额:
    $ 3.42万
  • 项目类别:
Elucidating Lung Cancer Etiology Among Asian American Female Never Smokers
阐明从不吸烟的亚裔美国女性肺癌病因
  • 批准号:
    9885673
  • 财政年份:
    2020
  • 资助金额:
    $ 3.42万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了